NCT05305651View on ClinicalTrials.gov

Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19

PHASE4CompletedINTERVENTIONAL
Enrollment

217

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

July 17, 2023

Study Completion Date

July 17, 2023

Conditions
COVID-19
Interventions
DRUG

Sotrovimab

Sotrovimab dose and administration per standard of clinical care

Trial Locations (8)

CB2 0QQ

GSK Investigational Site, Cambridge

CF14 4XW

GSK Investigational Site, Cardiff

B15 2GW

GSK Investigational Site, EdgbastonBirmingham

NW1 2BU

GSK Investigational Site, London

SE1 7EH

GSK Investigational Site, London

TS4 3BW

GSK Investigational Site, Middlesbrough

NE1 4LP

GSK Investigational Site, Newcastle upon Tyne

PL6 5FP

GSK Investigational Site, Plymouth

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT05305651 - Study to Monitor the Occurrence of Viral Variants in Patients With Compromised Immune Systems Being Treated for COVID-19 | Biotech Hunter | Biotech Hunter